Wu Wei

Discovery of in Vivo Chemical Probes for Treating Alzheimer's Disease: Dual Phosphodiesterase 5 (PDE5) and Class I Histone Deacetylase Selective Inhibitors.

O. Rabal, J. Oyarzábal, J. Sánchez-Arias, 2018, ACS chemical neuroscience.

Impact of Scaffold Exploration on Novel Dual-Acting Histone Deacetylases and Phosphodiesterase 5 Inhibitors for the Treatment of Alzheimer's Disease.

O. Rabal, J. Oyarzábal, J. Sánchez-Arias, 2017, ACS chemical neuroscience.

Design, Synthesis, and Biological Evaluation of First-in-Class Dual Acting Histone Deacetylases (HDACs) and Phosphodiesterase 5 (PDE5) Inhibitors for the Treatment of Alzheimer's Disease.

O. Rabal, J. Oyarzábal, J. Sánchez-Arias, 2016, Journal of medicinal chemistry.

Design, synthesis, biological evaluation and in vivo testing of dual phosphodiesterase 5 (PDE5) and histone deacetylase 6 (HDAC6)-selective inhibitors for the treatment of Alzheimer's disease.

O. Rabal, J. Oyarzábal, J. Sánchez-Arias, 2018, European journal of medicinal chemistry.